drugset / Trial / NCT07698054
Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a randomized, open-label, multi-center investigator-initiated clinical trial. Patients who meet the inclusion criteria receive the treatment plan stipulated in the protocol. A Bayesian design is used to explore the efficacy and safety of teprotumumab combined with pulse chemotherapy in the treatment of advanced second-line extensive-stage small cell lung cancer.
Timeline
- Start
- 2026-08-01
- Primary completion
- 2030-01-01
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Temozolomide | Small molecule | 75 mg/m2 | Oral |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |
| Background | Etoposide | Small molecule | 50 mg | Oral |